PRESS-NEWS.org - Press Release Distribution
PRESS RELEASES DISTRIBUTION

Scientists develop 'barcode' blood test for aggressive prostate cancer

2012-10-09
(Press-News.org) Scientists have designed a blood test that reads genetic changes like a barcode – and can pick out aggressive prostate cancers by their particular pattern of gene activity.

A team at The Institute of Cancer Research, London, and The Royal Marsden NHS Foundation Trust found reading the pattern of genes switched on and off in blood cells could accurately detect which advanced prostate cancers had the worst survival.

And the researchers believe the blood test could eventually be used alongside the existing PSA test at diagnosis to select patients who need immediate treatment.

The test, described in The Lancet Oncology today (Tuesday 9 October), is unique because it assesses changes in the pattern of gene activity in blood cells triggered by a tumour elsewhere in the body.

Study senior author Professor Johann de Bono, leader of the prostate cancer targeted therapy team at The Institute of Cancer Research, London, and honorary consultant at The Royal Marsden NHS Foundation Trust, said: "Prostate cancer is a very diverse disease – some people live with it for years without symptoms but for others it can be aggressive and life-threatening – so it's vital we develop reliable tests to tell the different types apart.

"We've shown it is possible to learn more about prostate cancers by the signs they leave in the blood, allowing us to develop a test that is potentially more accurate than those available now and easier for patients than taking a biopsy. Our test reads the pattern of genetic activity like a barcode, picking up signs that a patient is likely to have a more aggressive cancer. Doctors should then be able to adjust the treatment they give accordingly."

Researchers scanned all the genes present in blood samples from 100 patients with prostate cancer at the ICR's and The Royal Marsden's joint Drug Development Unit in London and The Beatson West of Scotland Cancer Centre in Glasgow. They included 69 patients with advanced cancer and 31 control patients thought to have low-risk, early-stage cancer, who were being managed by active surveillance.

Using statistical modelling, they divided the patients into four groups reflecting their pattern of gene activity – the barcode. When they reviewed all the patients' progress after almost two-and-a-half years, they found patients in one group had survived for significantly less time than patients in the others. Further modelling identified nine key active genes that were shared by all patients in the group.

They confirmed the results in another 70 US patients with advanced cancer, showing that just these nine genes could be used to accurately identify those who ultimately survived for a shorter time - 9.2 months compared with 21.6 months for patients without the gene pattern. The genes included a number involved in the immune system – suggesting the immune system was suppressed in patients whose cancers were spreading around the body.

Professor Alan Ashworth, chief executive of The Institute of Cancer Research, said: "Whether particular genes are active or not is an important clue in identifying patients with a poor prognosis. This latest study shows that it is possible to read these patterns of gene activity like a barcode, allowing scientists to spot cancers that are likely to be more aggressive."

Professor Martin Gore, medical director at The Royal Marsden, said: "Personalised medicine is the future of cancer treatment. This blood test, which reads genetic changes in prostate cancer providing a prediction of how aggressive the cancer might be, is an important development, allowing us to better tailor treatment to suit each individual."

### The study received funding from AstraZeneca, Prostate Cancer UK (formerly the Prostate Cancer Charity) and the Prostate Cancer Foundation, while the Drug Development Unit also receives funding from Cancer Research UK and the Experimental Cancer Medicine Centre network. Media Contact: ICR Science Communications Manager Jane Bunce on 0207
153 5106 or 07 721 747 900

Notes to editors:

"Prognostic value of blood mRNA expression signatures in castration resistant prostate cancer: a prospective two-stage study" will publish in The Lancet Oncology on 9 October 2012.

The scientists initially plan to assess the test as part of a large-scale international trial of a new prostate cancer drug in patients with advanced cancer. They also hope to assess the test in patients with earlier-stage disease, using either the existing nine-gene pattern or using the same technique to find another set of genes.

The Institute of Cancer Research, London, is one of the world's most influential cancer research institutes.

Scientists and clinicians at The Institute of Cancer Research (ICR) are working every day to make a real impact on cancer patients' lives. Through its unique partnership with The Royal Marsden and 'bench-to-bedside' approach, the ICR is able to create and deliver results in a way that other institutions cannot. Together the two organisations are rated in the top four cancer centres globally.

The ICR has an outstanding record of achievement dating back more than 100 years. It provided the first convincing evidence that DNA damage is the basic cause of cancer, laying the foundation for the now universally accepted idea that cancer is a genetic disease. Today it leads the world at isolating cancer-related genes and discovering new targeted drugs for personalised cancer treatment.

As a college of the University of London, the ICR provides postgraduate higher education of international distinction. It has charitable status and relies on support from partner organisations, charities and the general public.

The ICR's mission is to make the discoveries that defeat cancer. For more information visit www.icr.ac.uk The Royal Marsden NHS Foundation Trust The Royal Marsden opened its doors in 1851 as the world's first hospital dedicated to cancer diagnosis, treatment, research and education. Today, together with its academic partner, The Institute of Cancer Research (ICR), it is the largest and most comprehensive cancer centre in Europe treating over 44,000 patients every year. It is a centre of excellence with an international reputation for groundbreaking research and pioneering the very latest in cancer treatments and technologies. The Royal Marsden also provides community services in the London boroughs of Sutton and Merton and in June 2010, along with the ICR, the Trust launched a new academic partnership with Mount Vernon Cancer Centre in Middlesex. Since 2004, the hospital's charity, The Royal Marsden Cancer Charity, has helped raise over £50 million to build theatres, diagnostic centres, and drug development units. Prince William became President of The Royal Marsden in 2007, following a long royal connection with the hospital. For more information, visit www.royalmarsden.nhs.uk


ELSE PRESS RELEASES FROM THIS DATE:

Prenatal mercury exposure may be associated with risk of ADHD-related behaviors

2012-10-09
CHICAGO – A study of children in the New Bedford, Mass., area suggests that low-level prenatal mercury exposure may be associated with a greater risk of attention-deficit/hyperactivity disorder (ADHD)-related behaviors and that fish consumption during pregnancy may be associated with a lower risk of these behaviors, according to a report published Online First by Archives of Pediatrics & Adolescent Medicine, a JAMA Network publication. ADHD is one of the most common neurodevelopmental disorders of childhood and affects 8 percent to 12 percent of children worldwide, although ...

Study finds decline in HIV deaths for most men, women by race/ethnicity, education

2012-10-09
CHICAGO – Overall death rates due to human immunodeficiency virus (HIV) infection declined over time between 1993 and 2007 for most men and women by race/ethnicity and educational levels, with the largest absolute decreases for nonwhites, but rates remain high among blacks, according to a report published Online First by Archives of Internal Medicine, a JAMA Network publication. Widespread use of highly active antiretroviral therapy (HAART) has resulted in steep declines in HIV-related mortality, but not all groups have benefited equally from its availability. Many factors ...

Moving from high-poverty to low-poverty neighborhoods appears beneficial for some adolescent girls

2012-10-09
CHICAGO – Although some girls benefited from a program that moved families from high-poverty areas to low-poverty areas, boys and adolescents from families with preexisting health-related vulnerabilities did not appear to experience mental health benefits, according to a report published Online First by Archives of General Psychiatry, a JAMA Network publication. "Extensive observational evidence indicates that youth in high-poverty neighborhoods exhibit poor mental health, although not all children may be affected similarly," according to background information in the ...

Low-level mercury exposure in pregnant women connected to ADHD risk in children

2012-10-09
Boston, MA – Attention-deficit/hyperactivity disorder (ADHD) affects approximately ten percent of children worldwide, yet its causes are not well understood. Now, a study led by Susan Korrick, MD, MPH, of Brigham and Women's Hospital (BWH), and Sharon Sagiv, PhD, MPH, of Boston University School of Public Health, and published in the online version of the Archives of Pediatrics & Adolescent Medicine on October 8, 2012, links low-level prenatal mercury exposure with a greater risk of ADHD-related behaviors. The study also finds that maternal fish consumption during pregnancy ...

Adaptable button mushroom serves up genes critical to managing the planet's carbon stores

2012-10-09
The button mushroom occupies a prominent place in our diet and in the grocery store where it boasts a tasty multibillion-dollar niche, while in nature, Agaricus bisporus is known to decay leaf matter on the forest floor. Now, owing to an international collaboration of two dozen institutions led by the French National Institute for Agricultural Research (INRA) and the U.S. Department of Energy Joint Genome Institute (DOE JGI), the full repertoire of A. bisporus genes has been determined. In particular, new work shows how its genes are actually deployed not only in leaf decay ...

Leicester leads the way in most comprehensive ever hate-crime study

Leicester leads the way in most comprehensive ever hate-crime study
2012-10-09
Britain's most comprehensive study of hate crime is being launched this month in Leicester by a specialist research team at the University of Leicester. Criminologists from the University are starting a major two-year project, funded by the Economic and Social Research Council, examining the experiences of those who are victimised because of their identity, vulnerability or perceived 'difference' in the eyes of the perpetrator. Dr Neil Chakraborti and Jon Garland from the Department of Criminology at the University of Leicester said the research will broaden the scope ...

New MRI technique used to identify early-stage coronary disease

2012-10-09
OAK BROOK, Ill. – With the results of a magnetic resonance imaging (MRI) study from the National Institutes of Health (NIH), researchers say they are closer to finding an imaging technique that can identify thickening of the coronary artery wall, an early stage of coronary heart disease (CAD). The study is published online in the journal Radiology. "Imaging the coronary arteries that supply the heart with blood is extremely difficult because they are very small and constantly in motion," said lead researcher Khaled Z. Abd-Elmoniem, Ph.D., staff scientist in the Biomedical ...

Baruch College professor leads NIH study on weight loss interventions

Baruch College professor leads NIH study on weight loss interventions
2012-10-09
NEW YORK, NY-October 9, 2012 – A new National Institutes of Health (NIH)-funded study conducted at Baruch College and published in Obesity found that overweight and obese adults who participated in three different weight loss treatments, all involving intensive, multi-component counseling delivered in groups, lost significant weight after 48 weeks whether the treatment was led by a health professional or by someone who had previous weight loss success. This randomized clinical trial led by Angela Marinilli Pinto, PhD Assistant Professor of Psychology at Baruch College, ...

Healthy mom with lots of help key to thriving brood say scientists

2012-10-09
What does it take to raise successful, self-sufficient offspring? A healthy mom with lots of in-house help, says Utah State University researcher Dan MacNulty. While this advice may benefit humans, a recent study by MacNulty and colleagues actually focuses on another group of large, social mammals – namely, wolves. "Using 14 years of data from the long-term study of wolves in Yellowstone National Park, we examined a number of key traits that allow wolves to overcome environmental stress," says MacNulty, assistant professor in USU's Quinney College of Natural Resources. ...

Research on enhanced transmissibility in H5N1 influenza: Should the moratorium end?

2012-10-09
How can scientists safely conduct avian flu research if the results could potentially threaten, as well as save, millions of lives? In a series of commentaries appearing on Tuesday, October 9 in mBio®, the online open-access journal of the American Society for Microbiology, prominent microbiologists and physicians argue the cases both for and against lifting a voluntary moratorium on experiments to enhance the ability of the H5N1 virus to move from mammal to mammal, so-called "gain-of-function" research, and discuss the level of biosecurity that would be appropriate for ...

LAST 30 PRESS RELEASES:

University of Cincinnati experts present research at annual hematology event

ASH 2025: Antibody therapy eradicates traces of multiple myeloma in preliminary trial

ASH 2025: AI uncovers how DNA architecture failures trigger blood cancer

ASH 2025: New study shows that patients can safely receive stem cell transplants from mismatched, unrelated donors

Protective regimen allows successful stem cell transplant even without close genetic match between donor and recipient

Continuous and fixed-duration treatments result in similar outcomes for CLL

Measurable residual disease shows strong potential as an early indicator of survival in patients with acute myeloid leukemia

Chemotherapy and radiation are comparable as pre-transplant conditioning for patients with b-acute lymphoblastic leukemia who have no measurable residual disease

Roughly one-third of families with children being treated for leukemia struggle to pay living expenses

Quality improvement project results in increased screening and treatment for iron deficiency in pregnancy

IV iron improves survival, increases hemoglobin in hospitalized patients with iron-deficiency anemia and an acute infection

Black patients with acute myeloid leukemia are younger at diagnosis and experience poorer survival outcomes than White patients

Emergency departments fall short on delivering timely treatment for sickle cell pain

Study shows no clear evidence of harm from hydroxyurea use during pregnancy

Long-term outlook is positive for most after hematopoietic cell transplant for sickle cell disease

Study offers real-world data on commercial implementation of gene therapies for sickle cell disease and beta thalassemia

Early results suggest exa-cel gene therapy works well in children

NTIDE: Disability employment holds steady after data hiatus

Social lives of viruses affect antiviral resistance

Dose of psilocybin, dash of rabies point to treatment for depression

Helping health care providers navigate social, political, and legal barriers to patient care

Barrow Neurological Institute, University of Calgary study urges “major change” to migraine treatment in Emergency Departments

Using smartphones to improve disaster search and rescue

Robust new photocatalyst paves the way for cleaner hydrogen peroxide production and greener chemical manufacturing

Ultrafast material captures toxic PFAS at record speed and capacity

Plant phenolic acids supercharge old antibiotics against multidrug resistant E. coli

UNC-Chapel Hill study shows AI can dramatically speed up digitizing natural history collections

OYE Therapeutics closes $5M convertible note round, advancing toward clinical development

Membrane ‘neighborhood’ helps transporter protein regulate cell signaling

Naval aviator turned NPS doctoral student earns national recognition for applied quantum research

[Press-News.org] Scientists develop 'barcode' blood test for aggressive prostate cancer